Drilldown: Medicines

Dulaglutide (1)

Trulicity (1)

[[GLP-1 receptor agonist]] · [[Antidiabetic medicines|Antidiabetic]] · Fc-fusion biologic (1)

Long-acting agonist of the [[GLP-1 receptor]]; Fc-fusion construct. (1)

[[Type 2 diabetes mellitus]] · [[Cardiovascular risk reduction]] in T2DM (1)

0.75 mg SC weekly'"`UNIQ--ref-00000053-QINU`"' (1)

Pre-filled single-dose pen: 0.75 / 1.5 / 3 / 4.5 mg'"`UNIQ--ref-00000054-QINU`"' (1)

None · Indication-specific · 40 mg/d · 10 mg/d · 20 mg/d · 80 mg/d · 10 mg/d (adults) · 100 mg/d · 4 g/d · 400 mg/d · 40 mg/d typical; up to 240 mg/d for Zollinger-Ellison · 5 mg/d · 50 mg/d · 600 mg/d · No fixed ceiling; titrate to clinical effect and tolerability with CDC opioid prescribing guidance constraints on morphine-milligram-equivalent (MME) totals · No fixed maximum; titrated to TSH target · TID per eye · Titrated to glucose; no fixed ceiling · Titrated to glucose; no fixed maximum · '''20 mg/day in adults >60 years''' per FDA's 2011-2012 QT-prolongation warning; 40 mg/day in adults ≤60

Other values:

Search

None · Oral · IV · Topical · IM · Intranasal · rectal · subcutaneous · Topical ophthalmic · ophthalmic · intramuscular · intravenous · transdermal · vaginal · Subcutaneous (abdomen · sublingual · thigh · inhaled · intra-articular · nebulized

Other values:

Search

Glycemic effect within days; near-maximal HbA1c effect by 4 weeks at any given dose'"`UNIQ--ref-00000057-QINU`"' (1)

~7 days (weekly dosing)'"`UNIQ--ref-00000058-QINU`"' (1)

~5 days (~120 h)'"`UNIQ--ref-00000059-QINU`"' (1)

SC ~47%–65%'"`UNIQ--ref-0000005A-QINU`"' (1)

Avoid. Discontinue at least 1 month before planned pregnancy. Animal data show embryofetal harm.'"`UNIQ--ref-0000005B-QINU`"' (1)

Rx-only;'"`UNIQ--ref-0000005C-QINU`"' not a controlled substance (1)